The University of Nevada, Reno School of Medicine

Illuminate the Role of IL-13 Inhibitors for the Management of Atopic Dermatitis

Differentiate biologic therapies for atopic dermatitis (AD) targeting interleukin (IL)-13 based on their clinical profile

Review emerging clinical data for IL-13 biologics in the treatment of moderate-to-severe AD 

Examine strategies to optimize the use of IL-13 biologics for the long-term management of moderate-to-severe AD 

large_image (7).png

medium_image (7).png

small_image (7).png

thumbnail_image (7).png

image (7).png

Atopic dermatitis (AD) is a chronic, relapsing inflammatory dermatosis characterized by epidermal barrier dysfunction, type 2–skewed immune activation, and intense pruritus with eczematous lesions. Disease expression varies by age and severity, with recurrent flares and a well-established association with atopic comorbidities including asthma, allergic rhinitis, and food allergy.

This hub gathers the evidence, expert perspective, and practical insight shaping how atopic dermatitis is understood and treated today, connecting emerging therapies with the everyday decisions that define long-term care.

FC25: Illuminate the Role of IL-13 Inhibitors for the Management of Atopic Dermatitis

About

Learning Objectives

Intended Audience

Faculty

Accreditation Statement

Credit Designation Statement

Disclosures